Beaver Run Resort, Breckenridge, Colorado
January 29-30, 2007
Monday, January 29, 2007
7:00 AM Registration and Breakfast Session I: Cytokine Biology
8:00 AM IL-7 Signals Survival and Proliferation of T Cells
Scott Durum, NIH 8:25 AM The IL-10-related Cytokines as Novel Targets for Drug Development
Ray Donnelly, Ph.D., CDER, FDA
8:50 AM IL-20
Jes Thorn Clausen, Principal Scientist & Project Manager, Antibody & Cell Technology, Novo Nordisk 9:15 AM IL-22 is Produced by ThIL-17 Cells and Mediates IL-23 induced Dermal Inflammation and Acanthosis
Wenjun Ouyang, Ph.D., Scientist, Immunology Department, Genentech, Inc. 9:40 AM Negative Regulation of Interleukin 17 Expression and Th17 Differentiation
Jianfei Yang, Ph.D., Senior Scientist, Dept of Immunology & Inflammation, Boehringer Ingelheim 10:05 AM Refreshment Break 10:30 AM The Role of IL-23 in Development of Experimental Autoimmune Encephalomyelitis
Suzana Marusic, M.D., Ph.D., Lab Head, Principal Scientist, Wyeth Research 10:55 AM IL-18
William McPheat, Ph.D., AstraZeneca
11:20 AM Role of IL-1 Family Ligands in Skin Inflammation
Hal Blumberg, Ph.D., Senior Principal Scientist, Amgen
11:45 AM TWEAK: A novel Target for Treating inflammatory diseases
Linda Burkly, Ph.D., Distinguished Investigator, Biogen Idec, Inc. 12:10 PM Lunch and Ski Break
5:00 PM Poster Session & Opening Reception
7:00 PM KEYNOTE ADDRESS
Pathways for Blocking Cytokines and Reducing Inflammation
Charles Dinarello, M.D.
Professor of Medicine
University of Colorado, School of Medicine
Session I: Cytokine Biology (continued)
8:00 PM Alarmins Activate Immune Responses by Inducing Dendritic Cell Maturation
Joost Oppenheim, M.D., Chief, NCI, NIH 8:25 PM IL-27
Nancy Hosken, Senior Scientist, Autoimmunity & Inflammation, Zymogenetics 8:50 PM END OF DAY 1
Tuesday, January 30, 2007
7:00 AM Registration and Breakfast Session II: Inflammation and Cancer
8:00 AM Exploring the Role of IKK-beta in Inflammation and Cancer with Low Molecular Weight Inhibitors
Karl Ziegelbauer, Bayer Healthcare AG 8:25 AM Microenvironment and Cancer: Inflammation, microRNAs and Cytokines
Curtis Harris, M.D., Chief, Laboratory of Human Carcinogenesis, National Cancer Institute, NIH
8:50 AM Inflammation, Cytokines and Hepatocellular Carcinoma
Xin Wei Wang, Ph.D., Senior Investigator, Head, Liver Carcinogenesis Section, Laboratory of Human Carcinogenesis, National Cancer Institute, NIH
Session III: New Technologies in Cytokines
9:15 AM Novel Human Growth Hormone
Bruce Kimmel, Ph.D., Vice President, Therapeutic Applications, Ambrx 9:40 AM Refreshment Break 10:05 AM VelocImmune® and Cytokine Traps: Building Better Blockers
Drew Murphy, Vice President, Target Discovery, Regeneron Pharmaceuticals, Inc. 10:30 AM The Use of Gene Shuffling Technology to Develop Enhanced Interferon Alpha Molecules for the Treatment of Chronic Hepatitis C Infection
Julian Symons, Roche 10:55 AM Antibody-targeted Cytokines (immunocytokines): What Cytokine Works Best and in What Context?
Stephen Gillies, President, EMD Lexigen Research Center
11:20 AM Oral Presentations from Submitted Abstracts
Abstract Submission Deadline: December 29, 2006 11:50 AM Lunch Session IV: Chemokines
1:00 PM Non-conventional Approaches to Inhibiting Chemokines
Amanda Proudfoot, Ph.D., Director Collaborative Research, Serono 1:25 PM Modulation of Chemokines and Cytokines by Leukotriene B4
Anne Fourie, Ph.D., Principal Scientist, Johnson & Johnson Pharmaceutical Research & Development
Session V: Agonists and Antagonists
1:50 AM Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based Potent CCR2 Antagonists
Li Hu Yang, Ph.D., Director, Medicinal Chemistry, Merck & Co. 2:15 PM Refreshment Break 2:40 PM Advances in the Development of the CCR5 Antagonist, Vicriviroc, for HIV-1 Therapy
Julie Strizki, Ph.D., Principal Scientist, Schering-Plough 3:05 PM TLR-9 Agonists
Grayson Lipford, Ph.D., Director, Basic Research, Coley Pharmaceutical Group Inc.
3:30 PM A Small Molecule Inhibitor of Fibroblast/Myofibroblast Transformation and Fibrosis
John Park, Ph.D., Department of Pulmonary Research, Boehringer Ingelheim 3:55 PM Small Molecule Inhibitors for Cytokines
Brian Wong, Roche Palo Alto
4:20 PM JAK3 Inhibition: An Approach to Autoimmune Disease and Prevention of Transplant Rejection
Paul Changelian, Ph.D., Director of Inflammation Biology, Pfizer, Inc. 4:55 PM Conference Concludes
|
|
|
Invited Speakers:
|
|
KEYNOTE SPEAKER
Charles Dinarello, M.D.
University of Colorado School of MedicineHal Blumberg, Ph.D.
Amgen, Inc. Linda Buckly, Ph.D.
Biogen Idec, Inc. Paul S. Changelian, Ph.D.
Pfizer, Inc. Jes Thorn Clausen
Novo Nordisk Bruce Kimmel, Ph.D.
Ambrx, Inc. Raymond Donnelly, Ph.D.
CDER, FDA Scott Durum, Ph.D.
National Cancer Institute, NIH Anne Fourie, Ph.D.
Johnson & Johnson PRD Stephen D. Gillies, Ph.D.
EMD Lexigen Curtis C. Harris, M.D.
National Cancer Institute, NIH Nancy Hosken
ZymoGenetics, Inc. Grayson Lipford, Ph.D.
Coley Pharmaceutical Group Suzana Marusic, M.D., Ph.D.
Wyeth Research Drew Murphy, Ph.D.
Regeneron Pharmaceuticals Joost Oppenheim, M.D.
National Cancer Institute, NIH Wenjun Ouyang, Ph.D.
Genentech, Inc. John Bark, Ph.D.
Boehringer Ingelheim Julie Strizki, Ph.D.
Schering-Plough Julian Symons, D. Phil
Roche Xin Wei Wang, Ph.D.
National Cancer Institute, NIH Brian Wong
Roche Jianfei Yang
Boehringer Ingelheim Karl Ziegelbauer
Bayer AG Li Hu Yang, Ph.D.
Merck & Co. William McPheat, Ph.D.
AstraZeneca Amanda Proudfoot, Ph.D.
Serono
|
|